| Year |
Citation |
Score |
| 2006 |
Gárdián G. Animal models of Huntington's disease. Ideggyã³Gyã¡Szati Szemle. 59: 396-9. PMID 17203874 |
0.321 |
|
| 2006 |
Kiaei M, Petri S, Kipiani K, Gardian G, Choi DK, Chen J, Calingasan NY, Schafer P, Muller GW, Stewart C, Hensley K, Beal MF. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 2467-73. PMID 16510725 DOI: 10.1523/Jneurosci.5253-05.2006 |
0.689 |
|
| 2006 |
Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, Ferrante RJ, Kowall NW, Abeliovich A, Beal MF. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiology of Disease. 21: 541-8. PMID 16298531 DOI: 10.1016/J.Nbd.2005.08.018 |
0.728 |
|
| 2005 |
Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. The Journal of Biological Chemistry. 280: 556-63. PMID 15494404 DOI: 10.1074/Jbc.M410210200 |
0.707 |
|
| 2004 |
Klivenyi P, Gardian G, Calingasan NY, Yang L, von Borstel R, Saydoff J, Browne SE, Beal MF. Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. Neuromolecular Medicine. 6: 87-92. PMID 15970626 DOI: 10.1385/Nmm:6:2-3:087 |
0.74 |
|
| 2004 |
Gardian G, Yang L, Cleren C, Calingasan NY, Klivenyi P, Beal MF. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Medicine. 5: 235-41. PMID 15626823 DOI: 10.1385/Nmm:5:3:235 |
0.735 |
|
| 2004 |
Gárdián G, Vécsei L. Huntington's disease: pathomechanism and therapeutic perspectives. Journal of Neural Transmission (Vienna, Austria : 1996). 111: 1485-94. PMID 15480847 DOI: 10.1007/s00702-004-0201-4 |
0.313 |
|
| 2004 |
Klivenyi P, Starkov AA, Calingasan NY, Gardian G, Browne SE, Yang L, Bubber P, Gibson GE, Patel MS, Beal MF. Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. Journal of Neurochemistry. 88: 1352-60. PMID 15009635 DOI: 10.1046/J.1471-4159.2003.02263.X |
0.739 |
|
| 2004 |
Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry. 88: 576-82. PMID 14720207 DOI: 10.1046/J.1471-4159.2003.02160.X |
0.672 |
|
| 2003 |
Klivenyi P, Gardian G, Calingasan NY, Yang L, Beal MF. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Journal of Molecular Neuroscience : Mn. 21: 191-8. PMID 14645986 DOI: 10.1385/Jmn:21:3:191 |
0.735 |
|
| 2003 |
Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry. 86: 267-72. PMID 12807446 DOI: 10.1046/J.1471-4159.2003.T01-1-01868.X |
0.725 |
|
| 2003 |
Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Erratum: Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease (Journal of Neurochemistry (2003) 86 (267-272)) Journal of Neurochemistry. 87. DOI: 10.1046/J.1471-4159.2003.01868.X |
0.711 |
|
| Show low-probability matches. |